Daewon Pharmaceutical Co., Ltd. (KOSE:A003220) announces a share repurchase program. Under the program, the company will repurchase 378,549 shares pursuant to a contract with Best Investment & Securities and Hanyang Securities. The purpose of the program is to stabilize share prices and enhance shareholder value.

The repurchase program will continue until December 20, 2022. As of September 19, 2022, the company had 632,742 shares in treasury under the dividend capacity and no shares in treasury under other capacities.